Industry News
Pharmaceutical Industry News
Paving the way for the label…
Paving the way for the label update were results from the phase 3 Zenith trial, which was stopped early due to a positive efficacy signal.
AstraZeneca and Organon have been…
AstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling that both companies brought discredit on the industry.
Organon’s chief executive Kevin…
Organon’s chief executive Kevin Ali—who had been with the company since its 2021 debut—resigned from his role and exited the company’s board of directors Sunday, Organon said in a securities filing. The company’s EVP and
La testosterona devuelve a las mujeres su deseo sexual, pero hay algo más
No existe ningún producto de testosterona para mujeres aprobado por la FDA. Los seguros no la cubren y muchos médicos no la recetan. Aun así, se ha convertido en todo un fenómeno cultural.
FDA Approves New Menopause Drug to Treat Hot Flashes and Night Sweats
The drug, one of the few nonhormonal options for menopausal women, reduced hot flashes and night sweats, and appears to help with sleep issues.
Following a slight delay earlier…
Following a slight delay earlier this year—and a world-first green light in the U.K. over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for one of the most
Ipsen unveiled a new educational…
Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their pediatricians to adult care, for which they’re often unprepared.
Over the last 13 months, Sanofi…
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. On Friday, Sanofi reported that Dupixent achieved a new standard as quarterly
A cystic fibrosis buyers group has…
A cystic fibrosis buyers group has resurfaced in a bid to improve access to Vertex's expensive combination therapy Trikafta. Under the strategy, a much cheaper copycat of the modulator drug is slated to launch next
Last year, Japan’s Renalys picked…
Last year, Japan's Renalys picked up certain Asian rights to the IgAN medicine sparsentan from the medicine's developer, Travere Therapeutics. Chugai is set to take the medicine forward in the licensed countries under a new
After a negative advisory…
After a negative advisory committee vote and a postponed approval decision, the FDA opted to approve GSK's Blenrep in one of its two proposed combinations.
The company expects sales in the…
The company expects sales in the second half of the year to outpace those from the first and reiterated its annual revenue guidance, projecting growth between 20% and 21% for all of 2025.
To reach the target audience of…
To reach the target audience of geographic atrophy (GA) treatment Izervay, Astellas Pharma has turned to the “internet’s grandma,” cookbook author and popular social media creator Barbara “Babs” Costello.
Among a string of licensing deals…
Among a string of licensing deals from the week, Takeda's tie-up with Innovent stole the show. Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies. Asian biopharmas
Too old for pediatrics, too young…
Too old for pediatrics, too young for geriatrics - young adults with cancer are falling through the cracks. Here’s how we fix it.
In a new white paper, Havas Lynx…
In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency—use their platforms to battle rampant misinformation.
Even as Roche executives on…
Even as Roche executives on Wednesday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical sales led to a worse-than-expected third
Dermatology specialist Galderma…
Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and other skincare treatments
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.
Cambrex revealed plans to spend…
Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month that its owner was seeking a sale.